Stock fact sheet · data as of
Cardiff Oncology, Inc. (CRDF): fair value, margin of safety and Wheel Score
Healthcare · Biotechnology · United States · Speculative / Distressed
Is CRDF undervalued?
Cardiff Oncology, Inc. (CRDF) closed at 0.9710 on 16 Oct 2026, 3112% above the GLS average fair value of 0.0302. 1 of the 1 models that produced a number value the shares below the current price. A gap this wide usually means the market is paying for growth or a story the trailing numbers do not show yet; the models work from filed results, not forecasts, so they are conservative by design.
The average is built from just 1 models (DCF) - the rest returned nothing because an input they need (dividends, free cash flow, book value) is zero or negative - so treat it with more caution than usual.
The nightly engine files CRDF under Speculative / Distressed - negative earnings or a Piotroski score of 3 or less - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.
Nine valuation models for CRDF
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | 0.0302 | -97% | Present value of the projected free cash flows, discounted at the cost of capital |
| Graham Number | - | - | The most a defensive investor pays for the earnings and book value per share; no value tonight |
| Graham Growth | - | - | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight |
| Lynch | - | - | EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight |
| GLS Growth | - | - | EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight |
| 10 Cap | - | - | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | - | - | Earnings power value: current EPS capitalised at 9% with no growth; no value tonight |
| Zombie (liquidation) | 0.5609 | -42% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 2.00 | +106% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Cardiff Oncology, Inc. scores only 2 of 9 on the Piotroski F-score, which fails the Sunday Scan's "6 or more" rule. A reading this low means several of the basic tests - positive earnings, positive operating cash flow, falling debt, no new share issuance - are not met. A GLS Moat score of 2.2/10 is a weak reading: the ten-year history the score grades (revenue, EPS, book value, margins, cash flow, share count, ROIC) has not been steady, so the Moat part of the Wheel Score contributes little.
Returns on capital are thin or negative - ROIC -99.2%, ROE -101.0%, ROA -74.1% - with debt at 0.02 times equity and negative free cash flow.
Cardiff Oncology, Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Royalty 100% (fiscal year FY2020).
Institutional ownership scores 3/10, insider activity 10/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 2 / 9 | ROIC | -99.2% |
|---|---|---|---|
| GLS Moat | 2.2 / 10 | ROE | -101.0% |
| Debt / equity | 0.02 | ROA | -74.1% |
| Free-cash-flow yield | -54.2% | Payout ratio | 0% |
| Institutions | 3 / 10 | Insiders · Congress | 10 · 5 / 10 |
Wheel Score 22: Weak
With a Wheel Score of 22 Cardiff Oncology, Inc. sits in the Weak band. The parts - Value 0/25, Health 4/20, Moat 3/15, Premium 5/20, Stability 9/20 - show where: Value (0/25) scores lowest.
Implied volatility is 164%, far above the range the wheel strategy is built for. The premium looks generous; the Wheel Score gives it only 5 of 20 Premium points because moves of that size can blow through any strike. Chain open interest is 34,269 contracts across all expiries - enough for the wheel at normal size.
Volume runs at 454k shares a day on a market cap of $76M, with a beta of 1.42 - a high beta, so the stock tends to move more than the market and a strike can be gapped through; the Stability part of the Wheel Score gives that 9 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 0 / 25 | -3112% margin of safety | |
| Health | 4 / 20 | Piotroski 2/9 | |
| Moat | 3 / 15 | moat 2.2/10 | |
| Premium | 5 / 20 | implied volatility 164% | |
| Stability | 9 / 20 | 454k shares/day, $76M cap, beta 1.42 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
The next earnings report is due on 5 Nov 2026, 20 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Biotechnology
The 12 companies below are the closest to Cardiff Oncology, Inc. by market cap within the Biotechnology industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| ACRV Acrivon Therapeutics, Inc. Common Stock | 1.76 | 0.9553 | -84% | 8No options | $75M |
| OKYO OKYO Pharma Limited | 1.43 | 0.2145 | -567% | 13No options | $75M |
| NTRB Nutriband Inc. | 6.27 | - | - | 24No options | $76M |
| PMN ProMIS Neurosciences, Inc. | 8.29 | 1.50 | -452% | 12No options | $74M |
| TELO Telomir Pharmaceuticals, Inc. Common Stock | 1.05 | 0.1992 | -427% | 13No options | $77M |
| PTHS Pelthos Therapeutics Inc. | 20.25 | 92.90 | +78% | 36No options | $78M |
| PDSB PDS Biotechnology Corporation | 1.41 | 0.1443 | -877% | 23Weak | $79M |
| NTHI Neonc Technologies Holdings, Inc. | 2.75 | - | - | 27No options | $79M |
| INO Inovio Pharmaceuticals, Inc. | 1.04 | 0.6920 | -50% | 20Weak | $72M |
| HRTX Heron Therapeutics, Inc. | 0.3765 | - | - | 36Weak | $71M |
| MNOV MediciNova, Inc. | 1.45 | 0.6142 | -136% | 17Weak | $71M |
| NMRA Neumora Therapeutics, Inc. Common Stock | 0.4270 | 1.10 | +61% | 43Weak | $80M |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about CRDF
Is CRDF undervalued right now?
No: at 0.9710 the stock trades 3112% above the GLS average fair value of 0.0302 (data as of 16 Oct 2026), well beyond what trailing earnings, cash flow and book value support.
What is the Wheel Score of CRDF and what does it mean?
CRDF scores 22 out of 100 (Weak). The Wheel Score blends the margin of safety (25 points), Piotroski health (20), the GLS moat (15), the option premium on offer (20) and trading stability (20) into one number that ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned. 80 and above is Prime, 65-79 Good, 50-64 Fair, under 50 Weak.
What is the GLS fair value for CRDF?
0.0302 per share as of 16 Oct 2026 - the simple average of the 1 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Cardiff Oncology, Inc. report earnings next?
The next earnings report is due on 5 Nov 2026, 20 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does CRDF have listed options, and how liquid are they?
Yes. The nightly snapshot found 98 listed contracts with 34,269 open interest across all expiries and implied volatility of 164% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.